On Tuesday, Hain Celestial Group Inc(NASDAQ:HAIN)’s shares declined -3.27% to $55.87.
Celestial Seasonings®, a brand of The Hain Celestial Group, Inc. (NASDAQ: HAIN) and a leader in the specialty tea category since 1969, has introduced its new Celestial™ Organics premium tea offerings. Celestial Organics features nine new certified organic blends in two distinct lines: Herbal Teas and Teas for Wellness.
Celestial Organics features two product lines:
Celestial Organics Herbal Teas. These simple, delicious pairings of certified organic ingredients combine trend-forward botanicals like turmeric and cardamom with classic herbal tea favorites like chamomile and lemongrass. Celestial Organics Herbal Teas are accessible now in five varieties: Chamomile & Lavender, Cinnamon & Cardamom, Ginger & Turmeric, Lemon & Elderflower and Mint & Lemon Verbena.
Celestial Organics Teas for Wellness. These certified organic blends provide specific benefits for your body and support everyday wellness using only easily recognized ingredients. Whenever possible, these teas use pharmacopoeial grade botanicals to assure quality standards. Celestial Organics Teas for Wellness are accessible now in four varieties that address many of the top wellness needs of recently’s consumers: Detox Herbal Supplement, Digestion Herbal Tea, Immunity Herbal Supplement and Relaxation Herbal Supplement.
The Hain Celestial Group, Inc. manufactures, markets, distributes, and sells organic and natural products in the United States, the United Kingdom, Canada, and Europe. Its grocery products comprise infant formula; infant, toddler, and kids foods; diapers and wipes; rice and grain-based products; flour and baking mixes; breads, hot and cold cereals, pasta, condiments, cooking and culinary oils, granolas, granola bars, and cereal bars; canned, chilled fresh, aseptic, and instant soups; Greek-style yogurt; chilies and packaged grains; and chocolates and nut butters, in addition to plant-based beverages and frozen desserts, such as soy, rice, almond, and coconut.
Cogent Communications Holdings Inc(NASDAQ:CCOI)’s shares dropped -2.43% to $26.93.
Cogent Communications Holdings, Inc. (CCOI), one of the largest Internet service providers in the world, recently declared that Dave Schaeffer, Cogent’s Chief Executive Officer, will present at the Deutsche Bank 23rd Annual Leveraged Finance Conference at 8:00 a.m. MST, September 29th, 2015. The conference is being held at The Phoenician in Scottsdale, AZ.
Investors and other interested parties may access a live audio webcast of the conference presentations by going to the “Events” section of Cogent’s website at www.cogentco.com/events. A replay of the webcasts will be accessible for 90 days following the presentations.
Cogent Communications Holdings, Inc., through its auxiliaries, provides high-speed Internet access and Internet protocol communications services primarily to small and medium-sized businesses, communications service providers, and other bandwidth-intensive organizations in North America, Europe, and Japan.
At the end of Tuesday’s trade, Canadian Solar Inc.(NASDAQ:CSIQ)‘s shares dipped -4.36% to $18.21.
Canadian Solar Inc. (CSIQ), one of the world’s largest solar power companies, recently declared that the Company has reached a long term product supply agreement with Vivint Solar (VSLR), a leading provider of distributed solar energy to residential and commercial customers in the United States. This contract, which allows for Canadian Solar to supply Vivint Solar with high efficiency CS6P polycrystalline modules for residential and commercial installations, will give the Company the ability to reach additional customers within these market segments and expand its consumer base.
Canadian Solar Inc., together with its auxiliaries, designs, develops, manufactures, and sells solar wafers, cells, and solar power products worldwide. The company operates in two segments, Module and Energy. Its products comprise various solar modules that are used in residential, commercial, and industrial solar power generation systems.
Galena Biopharma Inc(NASDAQ:GALE), ended its Tuesday’s trading session with -2.66% loss, and closed at $1.83.
Galena Biopharma, Inc. (GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, recently declared that data from the Company’s Phase 2a portion of the Phase 1/2a clinical trial of GALE-301, or Folate Binding Protein, will be presented at the forthcoming European Society for Medical Oncology (ESMO) European Cancer Congress 2015 in Vienna, Austria.
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products comprise Abstral, a sublingual tablet that is used for the administration of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
